TargetMol

Garcinone C

Product Code:
 
TAR-TN1673
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TN1673-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1673-1mg1mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1673-5mg5mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN1673-10mg10mg£226.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Garcinone C is a xanthone derivative extracted from Garcinia oblongifolia Champ with anti-inflammatory, astringency, and granulation-promoting activities. Garcinone C is an AChE inhibitor and has potential cytotoxic effects on certain cancers.
CAS:
76996-27-5
Formula:
C23H26O7
Molecular Weight:
414.454
Pathway:
Microbiology/Virology; DNA Damage/DNA Repair; Stem Cells; PI3K/Akt/mTOR signaling; Neuroscience; JAK/STAT signaling; Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
CC(C)=CCc1c(O)cc2oc3cc(O)c(O)c(CCC(C)(C)O)c3c(=O)c2c1O
Target:
ATM/ATR; CDK; STAT; AChR; Antifection

References

Seesom W, et al. Antileptospiral activity of xanthones from Garcinia mangostana and synergy of gamma-mangostin with penicillin G. BMC Complement Altern Med. 2013 Jul 19;13:182. Xia Y, et al. Garcinone C exerts antitumor activity by modulating the expression of ATR/Stat3/4E BP1 in nasopharyngeal carcinoma cells. Oncol Rep. 2018 Mar;39(3):1485-1493.